Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia

OBJECTIVE: To evaluate the long-term safety and efficacy of deutetrabenazine in patients with tardive dyskinesia (TD). METHOD: Patients with TD who completed the 12 week, phase 3, placebo-controlled trials were eligible to enter this open-label, single-arm study. The open-label study consisted of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernandez, Hubert H, Stamler, David, Davis, Mat D, Factor, Stewart A, Hauser, Robert A, Jimenez-Shahed, Joohi, Ondo, William G, Jarskog, L Fredrik, Woods, Scott W, Bega, Danny, LeDoux, Mark S, Shprecher, David R, Anderson, Karen E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Movement Disorders
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902058/
https://www.ncbi.nlm.nih.gov/pubmed/31296586
http://dx.doi.org/10.1136/jnnp-2018-319918

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902058/
https://www.ncbi.nlm.nih.gov/pubmed/31296586
http://dx.doi.org/10.1136/jnnp-2018-319918

Ejemplares similares